NCT03606590 - Effect of Tumor Treating Fields (TTFields, 150kHz) Concomitant with Sorafenib for Advanced Hepatocellular Carcinoma (HCC) (HEPANOVA) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 15, 2019

Primary Completion Date

January 14, 2021

Study Completion Date

January 14, 2021

Conditions

Hepatocellular Carcinoma

Interventions

DEVICE

NovoTTF-100L(P) device

Patients will be treated continuously with the NovoTTF-100L(P) device. NovoTTF-100L(P) treatment will consist of wearing four electrically insulated electrode arrays on the abdomen. The treatment enables the patient to maintain regular daily routine.

DRUG

Sorafenib

Sorafenib 400 mg (2 x 200 mg tablets) taken twice daily without food (at least 1 hour before or 2 hours after a meal).

Trial Locations (8)

28050

HM Hospitales - Centro Integral Oncológico Clara Campal, Madrid

44093

CHU de Nantes, Nantes

79106

University Medical Center - University of Freiburg, Freiburg im Breisgau

89081

Ulm University Hospital, Ulm

779 00

University Hospital Fakultni Nemocnice Olomouc, Oncology Clinic, Olomouc

00128

Università Campus Bio-Medico di Roma, Rome

61-701

Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu, Poznan

Unknown

Vall d'Hebron Institute of Oncology (VHIO), Barcelona

All Listed Sponsors

lead

NovoCure Ltd.

INDUSTRY